PDCD1 and neoplasm: This retrospective cohort study (n=178) revealed that combination of angiotensin receptor blockers with PD-1/PD-L1 inhibitors resulted in further suppression of tumor growth in patients with metastatic urothelial carcinoma than when they were just treated with PD-1/PD-L1 inhibitors.